ArticleBMC pulmonary medicine2019
Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study.
Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Lung cancer resection in patients with underlying usual interstitial pneumonia: a meta-analysis.BMJ open respiratory research · 2023Pooled it
- Convergent Microenvironment Linking Idiopathic Pulmonary Fibrosis and Lung Cancer.Expert reviews in molecular medicine · 2026Review
- TGF-β Signaling as a Pathological Continuum Linking Idiopathic Pulmonary Fibrosis and Lung Cancer.Cells · 2026Review
- Article
- Retrospective analysis of the clinical features and prognosis of idiopathic pulmonary fibrosis combined with lung cancer.BMC cancer · 2025Article
- A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer.Journal of thoracic disease · 2025Review
- Usual Interstitial Pneumonia and Lung Cancer.Cureus · 2025Article
- Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review.Advances in respiratory medicine · 2025Review
- Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis.Respiratory research · 2025Review
- One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer.Translational lung cancer research · 2025Article
- Interstitial Lung Diseases and Lung Cancer: A Review on Similarities, Common Pathogenesis and Therapeutic Approach.Journal of personalized medicine · 2025Review
- The role of lung cancer in mortality rate in chronic fibrosing idiopathic interstitial pneumonia.Scientific reports · 2025Article
- Maize stover burning exposure accountable for remarkable environmental and health risk in broiler chickens.BMC veterinary research · 2025Article
- Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Serum biomarker changes in pulmonary fibrosis with lung cancer and their correlation with patient survival prognosis.American journal of cancer research · 2025Article
- A clinical and CT-based model for differentiating high-grade from low-grade lung adenocarcinoma in patients with idiopathic pulmonary fibrosis.American journal of translational research · 2025Article
- Causal effect of interstitial lung disease on lung cancer risk in never-smokers and prognostic insights from Mendelian randomization and transcriptome analysis.American journal of cancer research · 2025Article
- Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis.Journal of thoracic disease · 2024Article
- Lung Cancer and Interstitial Lung Diseases.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a common comorbidity of idiopathic pulmonary fibrosis (IPF) and has poor outcomes. The incidence and clinical factors related to development of lung cancer in idiopathic pulmonary fibrosis (IPF) are unclear. The aim of this study was to elucidate the cumulative incidence, risk factors, and clinical characteristics of lung cancer in IPF.
methodsIn this retrospective study, we analyzed clinical data for 938 patients who were diagnosed with IPF without lung cancer between 1998 and 2013. Demographic, physiologic, radiographic, and histologic characteristics were reviewed. Cumulative incidence of lung cancer and survival were estimated by the Kaplan-Meier method. Risk factors of lung cancer development were determined by Cox proportional hazard analysis.
resultsAmong 938 IPF patients without lung cancer at initial diagnosis, lung cancer developed in 135 (14.5%) during the follow-up period. The cumulative incidences of lung cancer were 1.1% at 1 year, 8.7% at 3, 15.9% at 5, and 31.1% at 10 years. Risk factors of lung cancer were male gender, current smoking at IPF diagnosis, and rapid annual decline of 10% or more in forced vital capacity (FVC). Patients who developed lung cancer were mostly elderly men with smoking history. Squamous cell carcinoma followed by adenocarcinoma was the most common histologic type. Lung cancer was frequently located in areas abutting or within fibrosis. Survival was significantly worse in patients with lung cancer compared to patients with IPF alone.
conclusionLung cancer frequently developed in patients with IPF and was common in current-smoking men with rapid decline of FVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.